Enhertu Phase III results to redefine how metastatic breast cancer is classifed
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
The facility will cater to the storage, handling and transportation of pharma, dairy products seafood among others
According to the state government, it will also provide support to special projects such as preclinical testing, genome sequencing in the private sector, private sector BSL-3 lab-vaccine development and manufacturing and testing and certification laboratories
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
The companies plan to use the proceeds to retire debt and expand operations
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
In the interim, Deepak Khanna will lead Human Health International.
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Subscribe To Our Newsletter & Stay Updated